MedTrace Logo

Safety Study to Evaluate BMS-830216 in Healthy Subjects

NCT00878020 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2011-02-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety profile, tolerability, and pharmacokinetics of single oral doses from 10 mg up to 1200 mg of BMS-830216 (pro-drug of BMS-819881) in healthy subjects

Conditions

Interventions

DRUG

BMS-830216

Capsules, Oral, Single Dose, 1 day

DRUG

Placebo

Capsules, Oral, 0mg, Single Dose, 1 day

DRUG

BMS-830216

Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days

DRUG

Placebo

Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00878020 on ClinicalTrials.gov